LEXINGTON, Mass.--(BUSINESS WIRE)--Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), announced today the ...
A recent review found that there were several modifiable and nonmodifiable factors that can affect the treatment adherence of patients with type 2 diabetes (T2D). Modifiable and nonmodifiable risk ...
Emerging diabetes therapies are transforming MASLD treatment by addressing both metabolic dysfunction and liver disease, with new approvals and a growing pipeline signaling a shift in care. A rapidly ...
Zacks Investment Research on MSN
LLY's next-gen obesity drug meets goal in first phase III study for T2D
Eli Lilly LLY announced positive top-line results from a late-stage study evaluating its experimental once-weekly weight-loss ...
Most patients with type 2 diabetes (T2D) showed partial non-adherence to antidiabetic therapy, with about one fourth of those prescribed an SGLT2 inhibitor not taking it. Partial non-adherence rose ...
Early data from the first phase III trial of Lilly’s triple agonist show reductions in weight and HbA1c for patients with ...
Eli Lilly and Company report top-line phase 3 clinical trial results for its investigational GLP-1, GIP, and glucagon agonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results